NanoString Appoints Mark Winham Senior Vice President of Operations

Oct. 2, 2019 10:00 UTC

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of Mark Winham as senior vice president of Operations effective October 2, 2019.

Mr. Winham worked for more than ten years in manufacturing for Applied Biosystems and Life Technologies, serving in positions of escalating responsibility from senior director to vice president of Global Manufacturing. As vice president of Global Manufacturing, Mr. Winham was responsible for more than 40 manufacturing sites worldwide that included over 2500 employees. This included a broad range of life science instruments and reagents that accounted for nearly $3 billion in annual revenue.

More recently, Mr. Winham has been employed by several start-up organizations including Wamberg Genomic Advisors, a global genomics advisory firm where he served as chief scientific and operating officer. Before that, Mr. Winham was chief operating officer for Human Longevity, Inc., a firm focused on developing and applying large-scale computing and machine learning to make novel scientific discoveries. From 2013 to 2015, Mr. Winham served as chief operating officer of Millennium Health, an innovative CLIA diagnostic laboratory. Mr. Winham received a B.S. in Life Sciences from Napier University in Edinburgh, Scotland.

“Mark is a veteran industry executive with more than 30 years of relevant life science experience and I’m thrilled to welcome him to the team,” said Brad Gray, NanoString’s president and CEO. “Mark brings deep operational experience that will be invaluable as we scale our business and introduce new platform technologies that will expand our addressable markets.”

“I’m excited to join the team at NanoString,” said Mr. Winham. “NanoString has a rich history of innovation and is poised for accelerating revenue growth fueled by new product introductions and the entry into spatial genomics.”

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 2,800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contacts

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

 

Source: NanoString Technologies, Inc.

Back to news